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Recent exon sequencing studies have revealed that
over 20% of human tumors have mutations in
subunits of mSWI/SNF (BAF) complexes. To investi-
gate the underlying mechanism, we studied human
synovial sarcoma (SS), in which transformation
results from the translocation of exactly 78 amino
acids of SSX to the SS18 subunit of BAF complexes.
We demonstrate that the SS18-SSX fusion protein
competes for assembly with wild-type SS18, forming
an altered complex lacking the tumor suppressor
BAF47 (hSNF5). The altered complex binds the
Sox2 locus and reverses polycomb-mediated
repression, resulting in Sox2 activation. Sox2 is
uniformly expressed in SS tumors and is essential
for proliferation. Increasing the concentration of
wild-type SS18 leads to reassembly of wild-type
complexes retargeted away from the Sox2 locus,
polycomb-mediated repression of Sox2, and cessa-
tion of proliferation. This mechanism of transforma-
tion depends on only two amino acids of SSX,
providing a potential foundation for therapeutic inter-
vention.
INTRODUCTION
Exon sequencing in human malignancy has provided paradigm-
changing insights into pathogenesis (Lander, 2011) but is often
limited by the fact that mutation frequencies are correlative,
leaving open the possibility that other primary events are respon-
sible for tumor initiation. This correlative aspect has emerged
particularly from recent exon-sequencing studies of human
cancers, which have defined frequent mutations in chromatin
regulators (Dawson and Kouzarides, 2012). By contrast, precise
chromosomal translocations, which define cancer subsets,
provide strong support for an initiating role. Chromatin regulation
has often been thought to play supportive roles, and hencea potential instructive or initiating function for chromatin regula-
tors in human cancer is less clear.
Chromatin regulation is essential for appropriate and timely
gene expression. This process is achieved by several mecha-
nisms, including DNA methylation, histone modifications, and
ATP-dependent chromatin remodeling. One of the most well-
characterized chromatin-remodeling complexes studied to
date is the SWI/SNF (BAF) complex, which was discovered in
yeast (Peterson and Herskowitz, 1992) and plays a general role
in gene activation through nucleosome remodeling, thereby al-
lowing accessibility of transcription factors to their recognition
sites. In flies, the Swi2/Snf2 ATPase homolog Brahma was
discovered in screens for trithroax genes (Tamkun et al., 1992)
and opposes polycomb function. Mammalian complexes have
two SWI2-like ATPases (Brg1 and Brm) and a second ATPase,
b-actin, and are combinatorially assembled from gene families
that encode the 15 subunits. Fewer than half of the subunits
are related to yeast SWI/SNF (others are related to RSC and
SWR1 subunits [Cairns et al., 1996; Krogan et al., 2003; Mizugu-
chi et al., 2004]), and hence the name BAF (Brg/Brm-associated
complexes) is commonly used. The complexes appear to have
undergone evolutionary changes in response to the emergence
of multicellularity, polycomb-mediated repression, DNA methyl-
ation, and a larger genome size (Wu et al., 2009). The role of
combinatorial assembly is seen most clearly in the mammalian
nervous system, in which neurons have a family of highly special-
ized neuron-specific complexes involved in dendritic morpho-
genesis (Lessard et al., 2007; Wu et al., 2007; Yoo et al., 2009).
Recent genetic studies in flies have suggested that the fly
homolog of the neural-specific BAF (nBAF) subunit BAF53b
has an instructive role in targeting dendritic trees to their correct
termini (Tea and Luo, 2011). Instructive roles are also suggested
from studies demonstrating that forcing the formation of nBAF
complexes leads to the conversion of fibroblasts to neurons
(Yoo et al., 2011). Specialized complexes are also found in
pluripotent cells (esBAF complexes) (Ho et al., 2009); recreating
the esBAF complex subunit composition in fibroblasts facilitates
iPS cell formation (Singhal et al., 2010). These recent studies
suggest an instructive role for these ATP-dependent chromatin
regulators that was not anticipated from earlier studies.Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc. 71
Recent exome sequencing studies of primary, early human
cancers have repeatedly discovered mutations to subunits of
polymorphic BAF complexes. Indeed, analysis of the 44
exome sequencing studies published to date indicate that
19.6% of all human cancers have mutations in at least one
subunit (C.K., D.C. Hargreaves, C.H. Hodges, L. Elias, L. Ho, J.
Ranish, and G.R.C., unpublished data). For example, BAF250a
is mutated in 57% of clear-cell ovarian cancers; BAF180 (poly-
bromo) is mutated in 41% of renal cancers (Varela et al., 2011);
and medulloblastomas have frequent mutations in Brg,
BAF53a, or BAF60b (Jones et al., 2012). The significance
of perturbation to ATP-dependent chromatin-remodeling
complexes in tumorigenesis has been most strongly demon-
strated in studies focusing on a particular class of tumors, malig-
nant rhabdoid tumors (MRTs), in which the subunit BAF47
(hSNF5) is biallelically inactivated in nearly 100% of cases re-
ported (Versteege et al., 1998). Patients often have inherited
a defective SNF5 allele, and the remaining wild-type allele is
lost in the tumors, implicating SNF5 as a tumor suppressor.
Conditional biallelic inactivation of Snf5 in mouse models results
in a fully penetrant phenotype with median onset to tumor devel-
opment at only 11 weeks (Roberts et al., 2002). The preference
for mutation of specific subunits in specific malignancies
suggests that different combinatorial assemblies have roles in
tissue-specific oncogenic processes, consistent with roles for
specialized BAF complexes in neurogenesis and other biologic
processes (de la Serna et al., 2001; Lickert et al., 2004; Wu
et al., 2009). Because of the possibility that the frequent BAF
subunit mutations might be playing a relatively nonspecific role
in oncogenesis, we initiated studies on a cancer type, human
synovial sarcoma (SS), in which nearly all tumors have a precise
translocation involving a specific subunit, indicating that the
translocation is the initiating oncogenic event.
Human synovial sarcoma accounts for 8%–10% of all soft-
tissuemalignancies andmost commonly arises in the extremities
of young adults (Weiss et al., 2001). A recurrent chromosomal
translocation, t(X;18)(p11.2;q11.2), fuses the SS18 gene on chro-
mosome 18 to one of three closely related genes on the X chro-
mosome, SSX1, SSX2, and rarely SSX4, resulting in an in-frame
fusion protein in which the eight C-terminal amino acids of SS18
are replaced with 78 amino acids (aa) from the SSX C terminus
(Clark et al., 1994; de Leeuw et al., 1995; Skytting et al., 1999).
This remarkably precise translocation is present in greater than
95% of cases and has been established as pathognomonic for
the disease with clinical diagnosis confirmed by karyotyping
andRT-PCR for SS18-SSX transcripts (Hiraga et al., 1998; Sand-
berg and Bridge, 2002). The presence of this translocation is the
defining feature of synovial sarcomas and is often the only cyto-
genetic abnormality (dos Santos et al., 1997; Limon et al., 1991);
hence, this is very likely to be the driving oncogenic event in the
development of these tumors. However, the mechanism of
SS18-SSX transformation has been unclear.
Both SS18 and SSX proteins lack known DNA binding motifs,
yet they appear to be acting through transcriptional regulatory
mechanisms. SS18 is a nuclear protein that has been suggested
to interact with chromatin-remodeling factors, such as the Brg/
Brm-containing complexes (Nagai et al., 2001; Thaete et al.,
1999), and the transformation potential of the SS18-SSX fusion72 Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc.has been shown to require Brg/Brm (Nagai et al., 2001). Fusion
partners SSX1, 2, and 4 are members of a family of nine human
SSX genes that encode highly similar proteins with 73%–92%
homology (cDNA homology 87%–96%) (Smith and McNeel,
2010) and conserved intron/exon junctions. SSX3 and SSX5
have not been found as fusion partners in tumors, although
they are highly similar to the oncogenic fusion partners. mRNA
expression of SSX genes is restricted to the testes and has
been detected at low levels in the thyroid.
Here, we demonstrate that SS18 is a dedicated, highly
stable subunit of BAF complexes. We find that the fusion of
SS18 with SSX produces a protein that binds to the complex
and evicts both the wild-type SS18 and the tumor suppressor
BAF47 (SNF5). This altered complex then binds to Sox2,
relieving H3K27me3 repression, thereby activating Sox2, which
we find is required for proliferation. Importantly, SS18-SSX-
driven complex disruption is determined by a 2 aa hydrophilic
region of SSX. Assembly of wild-type complexes and pro-
liferative quiescence can be achieved by increasing the concen-
tration of wild-type SS18, making this region an excellent drug
target.
RESULTS
SS18 Is a Subunit of Mammalian SWI/SNF-like BAF
Complexes
To better understand the composition of BAF complexes, we
used a rapid biochemical/affinity purification approach to isolate
endogenous complexes from nontransformed cells. Ammonium
sulfate fractionation was followed by rapid affinity purification
using a highly specific antibody to a genetically nonessential
epitope in the Brg/Brm ATPase subunit (Ho et al., 2009).
SS18 (Synovial sarcoma translocation, chromosome 18) pep-
tides were found in highly pure, endogenous BAF complexes in
all tissue types examined, with the exception of postmitotic adult
neurons. Numbers of peptides and percent coverage for the
protein SS18 were comparable to those of established BAF
complex subunits, suggesting it is a subunit of BAF complexes
(Figure 1A). Immunoprecipitation studies using anti-Brg as well
as antibodies specific to other established mSWI/SNF complex
components, including BAF250a, BAF155, and BAF47,
confirmed the association of SS18 with native BAF complexes;
similarly, reciprocal immunoprecipitation using an antibody to
SS18 revealed known components of BAF complexes (Figure 1B
and Figure S1A available online). Two bands are detected for
human SS18 due to alternative splicing (Figure S1B). Purification
of complexes using anti-Brg and anti-SS18 antibodies revealed
similar banding patterns upon silver stain analyses (Figure S1C).
In order to determinewhether SS18was dedicated exclusively to
BAF complexes, we performed glycerol gradient sedimentation
analyses that demonstrated the presence of SS18 only in
those fractions containing Brg and other BAF complex subunits
(fractions 12–15). SS18 did not associate with polycomb repres-
sive complexes PRC1 or PRC2, as indicated by Bmi1 or Ezh2
immunoblots, respectively, or as a free monomer in earlier frac-
tions of the gradient (Figure 1C). Results were comparable in
several cell types assayed, including cell lines ES E14, Raji,
293T, and CCRF-CEM, as well as primary human fibroblasts.
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Figure 1. SS18 Is a Dedicated, Stable Subunit of mSWI/SNF (BAF) Complexes
(A) Composition of BAF complexes isolated from ES cells, MEFs, and brain as determined by mass spectrometric analysis. See also Figure S1C.
(B) Immunoprecipitation (IP) using anti-Brg and anti-SS18 antibodies in 293T nuclear extracts (NEs). See also Figures 1A and 1B.
(C) Glycerol gradient (10%–30%) analysis on ES cell NEs.
(D) Left: Schematic for urea-based denaturation analyses. Right: Anti-Brg IPs on 293T NE preps treated with 0–5 M urea.
(E) Quantitative densitometry on urea denaturation immunoblots.Using urea-based denaturation studies, we determined that
SS18 was remarkably stably bound to the complex, to a greater
extent than most other subunits, including BAF47, BAF155, and
BAF 170, requiring denaturing conditions of greater than 5 M
urea to dissociate (Figures 1D and 1E), similar to ribosomal
subunits. The observation that SS18 remains bound when other
subunits have dissociated indicates that SS18 binds directly to
a stable core complex of Brg, BAF53a, and b-actin (Zhao
et al., 1998). These results demonstrate that SS18 is a dedicated
subunit of mSWI/SNF or BAF complexes, with binding charac-
teristics similar to those of ribosomal subunits.SS18-SSX Integrates into BAF Complexes and Alters
Complex Composition
The invariant molecular feature of human synovial sarcoma is the
SS18-SSX fusion protein, in which the C-terminal 78 aa of SSX
are fused in frame with aa1–379 of the SS18 subunit (Figure 2A).
To investigate the oncogenic mechanism, we used two biphasic
synovial sarcoma (SS) lines, Aska-SS and Yamato-SS, both of
which bear the SS18-SSX1 chromosomal translocation (Naka
et al., 2010). Anti-Brg immunoprecipitation studies performed
on nuclear extracts isolated from synovial sarcoma cell lines,
as compared to control 293T cells (and various other cell types),Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc. 73
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Figure 2. mSWI/SNF (BAF) Complexes Are Disrupted in Synovial Sarcoma Cells Bearing the SS18-SSX1 Fusion Protein
(A) Diagram of the SS18-SSX fusion protein resulting from t(x;18) translocation, hallmark to synovial sarcoma.
(B) Anti-Brg IP (left) and total protein (right) in 293T cells as compared to synovial sarcoma (SS) cell lines, Aska-SS, and Yamato-SS. See also Figures S2A–S2C.
(C) Glycerol gradient (10%–30%, fractions 1–20) analysis on Aska-SS cell NEs. See also Figures S2D and S2E.
(D) Side-by-side comparison of fractions 3,4 and 15,16 of Aska-SS glycerol gradient analysis.
(E) Immunodepletion studies performed on 293T and Aska-SS cells using anti-BAF155 and anti-SSX1 antibodies. Undepleted, antibody not added.demonstrated that when SS18 was fused to its translocation
partner SSX, the SS18-SSX1 fusion protein was indeed bound
to BAF complexes, as reflected by an appropriate upshift in
molecular weight of SS18 from 55 kDa to 66 kDa upon immuno-
blot analysis (Figure 2B, left). Remarkably, we observed that both
synovial sarcoma lines, as compared to several other cell types
assayed, exhibited lower to absent total protein levels of the
tumor suppressor subunit BAF47 (hSNF5 or INI1) (Figures 2B,
right, and S2A, left), while transcripts were largely comparable
(Figure S2A, right). Immunoprecipitated BAF complexes con-
taining the SS18-SSX1 fusion protein showed nearly absent
levels of wild-type SS18 on the complex. Input protein levels of
the wild-type-sized SS18 protein were also lowered, as were
mRNA levels, suggesting reduced transcription (Figure S2B),
consistent with previously reported findings (Brodin et al.,74 Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc.2001). In addition, a prominent Brg peak is located at the
promoter and in an intronic region of the SS18 gene as deter-
mined by chromatin immunoprecipitation (ChIP)-seq analysis
in murine ES cells (Figure S2C) (Ho et al., 2011), suggesting au-
toregulation of this locus. Density sedimentation analyses per-
formed on nuclear extracts isolated from Aska-SS and
Yamato-SS lines revealed disruption of BAF complex composi-
tion, in that wild-type SS18 protein no longer associated with the
BAF complex fractions (fractions 15,16) and rather existed in
fractions 3 and 4, suggesting its presence as amonomer (Figures
2C and S2D). Quantitative densitometry of an anti-SS18 immu-
noblot of the glycerol gradient revealed that only a small
percentage (2%–8%) of BAF complexes contain the wild-type
SS18 protein in these cells (Figure S2E). Side-by-side molecular
weight comparisons indicated that the SS18-SSX fusion protein,
in both SS lines, was almost entirely associated with the BAF
complex (denoted by Brg peaks in fractions 15,16) and the
wild-type SS18 protein was present, albeit at lower protein
levels, in the monomeric fractions of the gradient (fractions 3,4)
(Figure 2D). This was further confirmed by immunoblotting using
an anti-SSX1 antibody, which demonstrated the presence of
SSX1 only in fractions containing Brg. As shown above, in SS
lines containing the SS18-SSX fusion, BAF47 no longer associ-
ated with BAF complexes and was nearly absent from nuclear
extracts indicative of degradation. This is particularly interesting
given that BAF47 is a known tumor suppressor; loss of this
subunit from the complex as a result of the integration of
SS18-SSX might produce functional consequences similar to
those of SNF5 inactivation. In order to further assess the degree
of dedication of SS18 and SS18-SSX to the BAF complex, we
performed depletion studies using two rounds of immunoprecip-
itation with polyclonal antibodies specific to a known complex
subunit, BAF155, as well as to SS18’s fusion partner, SSX1
(Figure 2E). In 293T cells, BAF155 antibodies depleted SS18
protein from the nuclear extracts; SSX1 antibody did not deplete
the lysate, as expected, in the wild-type setting. In the Aska-SS
cell line, immunodepletion using the SSX1 antibody significantly
depleted complex subunits Brg, BAF155, and SS18-SSX
proteins from nuclear extracts to comparable levels as with
anti-BAF155 antibody. These results collectively demonstrate
that both wild-type SS18 and the SS18-SSX1 fusion protein in
synovial sarcoma are dedicated to BAF complexes but that the
fusion protein alters subunit composition.
To understand how incorporation of SS18-SSX alters the
biochemical subunit composition of BAF complexes, we
produced N-terminally GFP-tagged constructs of SS18 FL (full
length, aa1–387), SS18 aa1–379 (lacking the last C-terminal 8
aa, which are lost in the fusion), and SS18-SSX using a
pEGFP-based expression system (Figure 3A). Previous studies
have established that the N-terminal SNH domain of SS18 is
responsible for its BAF complex association (Nagai et al.,
2001). Anti-GFP immunoprecipitations were performed to isolate
those BAF complexes that had incorporated the exogenously
introduced SS18 or SS18-SSX variants. Intriguingly, we found
that expressing the SS18-SSX fusion protein resulted in the
loss of BAF47 from the complex at 72 hr posttransfection (Fig-
ure 3B). Wild-type SS18 FL or SS18 1–379 both incorporated
into BAF complexes but did not alter BAF47 binding to the
complex. Input levels of BAF47 at this time point (72 hr), following
introduction of SS18-SSX (and all variants tested), were compa-
rable to those of untreated cells. Immunoblot analysis performed
on total input protein harvested at 96 hr posttransfection with
SS18-SSX indicated a marked decrease in BAF47 levels, while
mRNA levels remained stable, suggesting that BAF47 is first
lost from the complex upon integration of SS18-SSX and subse-
quently degraded (Figures 3C and S3). To understand themeans
by which BAF47 is degraded under normal conditions, we per-
formed cyclohexamide (CH) chase experiments over 24 hr,
plus and minus proteasome inhibitor treatment using MG-132
at the 24 hr time point. The protein half-life of BAF47was approx-
imately 10 hr after the addition of CH; BAF47 levels could be
rescued from CH treatment with MG-132 to >85% of control
levels, indicative of proteasome-mediated degradation (Fig-ure 3D). Treatment of Aska-SS cells with MG-132 resulted in
a substantial increase in BAF47 total protein levels (Figure 3E).
Upon infection of SS18-SSX1 into 293T fibroblasts, wild-type
SS18-containing complexes were readily replaced by SS18-
SSX-containing complexes (fractions 14,15,16), and BAF47
levels were reduced as determined by glycerol gradient analyses
(Figure 3F). Wild-type SS18 was observed in free, monomeric
fractions of the glycerol gradient (fractions 3–5), as well as Brg-
associated fractions 9–11 (likely indicative of partially formed,
lower molecular weight complexes). These studies indicate
that the SS18-SSX fusion incorporates into BAF complexes, re-
placing wild-type SS18 and ejecting and destabilizing BAF47.
To understand whether low protein levels of BAF47 result
specifically from the presence of the SS18-SSX1 fusion in SS
cells, we generated shRNA-based knockdown (KD) constructs
specific for the 30 UTR of SSX (based on Takenaka et al., 2010)
to exclusively target SS18-SSX, but not wild-type SS18.
Remarkably, we noted a substantial increase in BAF47 total
protein levels upon KD of the SS18-SSX oncogenic fusion
(Figure 3G). In addition, wild-type SS18 protein levels increased,
suggesting relieved repression of SS18 upon KD of the SS18-
SSX fusion. We assessed the effect of SS18-SSX KD on prolifer-
ation of both synovial sarcoma cell lines. Importantly, KD of the
SS18-SSX fusion and of Brg, to which the SS18-SSX fusion
was bound, resulted in a profound decrease in proliferation of
synovial sarcoma cells (Figure 3H). By contrast, KD of wild-
type SS18 and BAF47, subunits not contained in the SS18-
SSX-containing BAF complexes, had little to no effect on syno-
vial sarcoma cell proliferation (Figure 3H), suggesting that the
aberrant residual complex is responsible for driving and main-
taining cell proliferation. In human primary fibroblasts with
wild-type complexes, KD of Brg, SS18, and BAF47 reduced
proliferation; KD of SS18-SSX1 did not alter proliferation as
compared to control hairpin (Figure 3I). These studies indicate
that the eviction of BAF47 inactivates it and that it is no longer
required for proliferation of the SS cell lines. Hence, the free
BAF47 protein does not acquire a new function enabling
transformation.
Synovial Sarcoma Cell Gene Expression Features
Recapitulated: SS18-SSX Induces Sox2 Expression
Several studies have demonstrated that SS cells harbor stem-
cell-like gene expression profiles (Garcia et al., 2012; Naka
et al., 2010). Moreover, Roberts and colleagues observed that
tumors lacking the BAF47 tumor suppressor subunit also
express stem-cell-like signatures (Wilson et al., 2010). Naka
and colleagues demonstrated that Aska-SS and Yamato-SS
lines, as well as 15/15 human tumor specimens of synovial
sarcoma tested, express mRNA transcripts of pluripotency
factors Sox2, Oct4, and Nanog (Naka et al., 2010). We focused
on Sox2 because of its role in oncogenesis (Bass et al., 2009).
Introduction of SS18-SSX dramatically induced Sox2 mRNA in
primary, untransformed human neonatal foreskin fibroblasts by
15 days postinfection and selection (Figure 4A). This induction
was specific to the full SS18-SSX1 fusion and did not occur
when the C-terminal 34 aa of the conserved SSXRD domain
were removed from SSX1. To determine if Sox2 mRNA induction
was driven by the partially formed complexes, we tested theCell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc. 75
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Figure 3. SS18-SSX1 Ejects BAF47 and Wild-Type SS18 to Recapitulate BAF Complex Phenotype in Synovial Sarcoma Cells
(A) N-terminal GFP-tagged constructs of SS18 FL, SS18 1–379 (8 aa), and SS18-SSX.
(B) Anti-GFP IP of BAF complexes 72 hr posttransfection with various pEGFP constructs in 293T fibroblasts. See also Figure S3.
(C) Immunoblot analysis on total protein isolated from transfected 293T cells at time t = 0 to t = 168 hr posttransfection with GFP-SS18-SSX.
(D) Top: Cyclohexamide (CH) chase treatment of 293T cells, t = 0 to t = 24 hr, ± MG-132 proteosome inhibitor. Bottom: Quantitative densitometry of BAF47
protein levels on immunoblot.
(E) Immunoblot analysis for BAF47 protein in Aska-SS cells treated with MG-132 proteosome inhibitor for t = 8 and t = 16 hr.
(F) Glycerol gradient analyses on 293T cells infected with lentivirus (LV) containing either empty vector (top half) or SS18-SSX (bottom half).
(G) shRNA-mediated knockdown (KD) of SS18-SSX and wild-type SS18 in Aska-SS cells.
(H) Cell proliferation analyses of Aska-SS cells infected with shScramble control vector or delivery constructs containing shRNA KD to BAF subunits. Cells plated
in triplicate at 105 cells/well per condition. Error bars, SD of n = 3 experiments.
(I) Cell proliferation analyses of human primary neonatal foreskin fibroblasts infected with shScramble control vector or shRNAKD to BAF complex subunits. Cells
plated in triplicate at 105 cells/well per condition. Error bars, SD of n = 3 experiments.
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Figure 4. SS18-SSX1 Induces Sox2 mRNA Expression, which Drives SS Cell Proliferation
(A) Sox2 mRNA levels at day 10 postinfection with LV containing either SS18/SS18-SSX variants or shRNAs to BAF complex subunits. (Normalized to GAPDH;
***p < 0.005, **p < 0.01, error bars reflect SD in n = 5 separate experiments.) See also Figure S4A.
(B) Time course of Sox2, Oct4, and Nanog mRNA levels postinfection with SS18-SSX-containing LV. (Normalized to GAPDH; error bars reflect SD in n = 5
separate experiments.)
(C) shRNA-mediated knockdown of Sox2 in Aska-SS cells: top, immunoblot analysis; bottom, Sox2 mRNA levels.
(D) Proliferative analysis of Aska-SS cells treated with Sox2 shRNA KD LV. Control, shScramble.
(E) Left: Immunoblot analysis on Aska-SS cells treated with shControl or with either shSS18-SSX1 or shSox2-1. Right: Sox2 mRNA relative expression
(normalized to GAPDH).
(F) Left: Anti-BAF155 ChIP on human primary fibroblasts treated with either empty vector or SS18-SSX1, with subsequent qPCR for regions at the human Sox2
promoter and two Sox2 transcription factor (TF) binding sites within the exon. Right: Anti-H3K27me3 ChIP. Error bars, SD of n = 3 experiments. See also Figures
S4B and S4C.
Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc. 77
A B
C
D
E F G
H
(legend on next page)
78 Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc.
effect of shRNA-mediated KD of SS18 and BAF47 in fibroblasts
on Sox2 mRNA induction. Intriguingly, KD of SS18 and BAF47
both resulted in a statistically significant increase in Sox2
mRNA to levels nearly comparable to those resulting from over-
expression of SS18-SSX (Figure 4A). At the protein level, BAF47
and SS18 appear to reciprocally regulate one another’s stability
in fibroblasts as determined by KD of BAF47 and SS18 and
immunoblot analysis for protein levels of each (Figure S4A). KD
of Brg alone resulted in >70% reduction in protein levels, but
did not induce Sox2. Collectively, these data suggest that the
activity of aberrant complexes, which lack BAF47 and wild-
type SS18, are responsible for Sox2 mRNA induction. Sox2
mRNA levels increased 23-fold by day 25 postinfection with
SS18-SSX1 as compared to control (Figure 4B). Oct4 and Nanog
mRNA were not induced significantly.
We sought to determinewhether Sox2was important for syno-
vial sarcoma cell proliferation. To this end, we generated lenti-
virus containing two different shRNA hairpins to Sox2, both of
which effectively reduced Sox2 mRNA and protein in Aska SS
cells (Figure 4C), and assessed proliferative capacity in vitro.
shRNA-mediated KD of Sox2 profoundly reduced proliferation
of Aska-SS cells as compared to scrambled shRNA control
(Figure 4D). Intriguingly, upon KD of the SS18-SSX1 fusion,
Sox2 mRNA and protein levels were reduced in Aska-SS cells
to levels comparable to those of cells treated with Sox2 shRNA
itself (Figure 4E), indicating that elevated levels of Sox2 were
specifically due to the presence of SS18-SSX fusion.
To understand the mechanism of Sox2 induction by SS18-
SSX, we assessed BAF complex occupancy at the Sox2
promoter as well as two clusters of transcription factor (TF)
binding sites within the Sox2 exonic region using our affinity-
purified BAF155 polyclonal antibody. Intergenic regions were
selected as normalization controls. SS18-SSX1-infected primary
human fibroblasts demonstrated a significant increase in BAF
complex occupancy at all three sites within the human Sox2
locus as compared to control fibroblasts (Figure 4F). In MEFs,
there is a prominent H3K27me3 peak over the Sox2 locus as
shown byMEFChIP-seq studies (Mikkelsen et al., 2007), consis-
tent with absent Sox2 expression in these cells (Figure S4B).
Lentiviral introduction of SS18-SSX1 into primary human fibro-
blasts resulted in a striking decrease in H3K27me3 enrichment
at all three sites tested within the Sox2 locus (Figure 4F).
To determine if the 78 aa tail of SSX was itself responsible for
the targeting of BAF complexes to the Sox2 locus (perhaps by
binding a transcription factor), we infected human fibroblasts
with V5-tagged SSX78aa (as well as SS18 FL and SS18-SSX).Figure 5. Molecular Requirements of the 78 aa SSX Peptide for BAF47
(A) Left: Immunoblot analysis for BAF47 and Brg on anti-Brg IPs (top) of 293T
Quantitative densitometry depicting BAF47/Brg protein ratios in IP studies.
(B) Sox2 mRNA levels in human fibroblasts day 15 postinfection with LV contain
(C) Hydrophobicity determination using the Kyte-Doolittle algorithm for 78 C-term
highlighted in yellow.
(D) Peptide alignment of SSX1- SSX5 C-terminal 78 aa. Pink arrows indicate amin
SSX5; yellow highlight indicates regions determined to be critical for BAF47 ejec
(E and F) Immunoblot analysis for BAF47 and Brg on anti-GFP IPs of 293T cells t
SS18-SSX1, SS18-SSX1Daa43,44 (KR/MI), SS18-SSX3, and SS18-SSX3Daa4
(G) Quantitative densitometry depicting BAF47/Brg protein ratios in IP studies. E
(H) Sox2 mRNA levels in human fibroblasts day 15 postinfection with LV containHowever, we did not find that the 78 aa SSX fragment localized
to the Sox2 locus (Figure S4C). These studies indicate that the
SS18-SSX fusion functioning within the altered BAF complexes
binds to and activates the Sox2 locus in fibroblasts by disrupting
H3K27me3-mediated repression, which is likely directed by the
actions of PRC2, the only complex known to place this mark
(Chamberlain et al., 2008).
Molecular Requirements of SS18-SSX for BAF47
Ejection from BAF Complexes
Because expression of SS18-SSX1 resulted in the ejection and
subsequent degradation of the BAF47 subunit, we aimed to
understand the features of the 78 aa SSX tail that could be
responsible for this. We generated a series of truncation
mutants: deleting the conserved SSXRD domain of 34 aa,
deleting half of the SSXRD domain (17 aa, hydrophobic), and
adding amino acids in increments of 10 aa to the SS18 C
terminus (+10 through +70). We noted that SS18+10 through
SS18+70 did not result in significant ejection of BAF47 from
the complex as determined by immunoblot analysis and
quantitative densitometry performed on immunoprecipitated
complexes (Figure 5A). This implies that a region in the last 8
aa (SDPEEDDE) is required for BAF47 ejection. Deleting
1/2SSXRD resulted in slightly decreased levels of BAF47.
Upon introduction of these variants into human fibroblasts,
Sox2 mRNA induction was only observed with SS18-SSX1
(Figure 5B). Because none of these truncationmutants fully reca-
pitulated the SS18-SSX1-induced BAF47 ejection and Sox2
mRNA induction phenotype, we turned to the fact that the only
translocations that have been observed in human synovial
sarcoma are SS18-SSX1, SS18-SSX2, and SS18-SSX4. SS18-
SSX3 has never been observed in a human tumor. This family
of nine genes (SSX1-9) located at ch Xp11.2 is highly similar;
protein homology among members ranges from 73%–93%
(Smith and McNeel, 2010). We used Kyte-Doolittle hydropho-
bicity analysis to compare the 78 C-terminal aa of SSX1,2,4
versus SSX3, which revealed a significant difference in hydro-
phobicity between aa40–50 (Figure 5C), as highlighted. Upon
peptide alignment of the 78 aa of SSX1–4, it became clear that
the amino acid composition at position 43, 44 was most
discrepant between the SSX members observed in human SS
tumors (1,2 and 4) and the nononcogenic SSX3. SSX1,2,4
contains lysine (K) and arginine (R), glutamic acid (E) and arginine
(R), and lysine (K) and threonine (T), respectively, at position
43,44, whereas SSX3 contains a methionine (M) and isoleucine
(I) at these positions (Figure 5D, arrows). Given that SSX1 isSubunit Ejection from mSWI/SNF-like BAF Complexes
cells transfected with various SS18/SS18-SSX constructs (bottom). Right:
ing SS18 and SS18-SSX variants. Error bars = SD.
inal amino acids (aa) of SSX1-SSX4 proteins. Region of significant difference
o acids of significant difference between SSX1/2/4 and SSX3 or SSX1/2/4 and
tion.
ransfected (E) with constructs as per above as well as SS18-SSX3 and (F) with
3,44 (MI/KR). See also Figure S5A.
rror bars = SD.
ing various constructs. See also Figure S5B. Error bars = SD.
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a common fusion partner of SS18 in synovial sarcoma and SSX3
is not, we then sought to understand if SSX3 fused to SS18 could
result in BAF47 ejection and Sox2 induction. To this end, we
generated an SS18-SSX3 fusion protein (379 aa of SS18 fused
to 78 aa of the SSX3 C terminus). SS18-SSX3 was able to inte-
grate into BAF complexes, as assessed by anti-GFP immuno-
precipitation of BAF complexes, but failed to eject BAF47
(Figure 5E) from the complexes. Remarkably, replacement of
amino acids 43,44 of SSX1 (KR) with those of SSX3 (MI) in the
SS18-SSX1 fusion resulted in substantial loss of the ability to
displace BAF47 (Figure 5F). Reciprocal amino acid substitution
at position 43,44 in SS18-SSX3 (MI to KR) resulted in the gained
ability of SS18-SSX3 to eject BAF47. Comparative densitometry
accounting for the BAF47/Brg ratio is shown, representative of
n = 3 experiments (Figure 5G). Intriguingly, SS18-SSX1, as well
as SS18-SSX3 (D43,44 MI/KR), significantly induced Sox2
mRNA; no other variant produced this phenotype (Figure 5H),
lending further evidence that the loss of BAF47 (hSNF5) from
mSWI/SNF complexes is necessary for the induction of Sox2
mRNA expression in synovial sarcoma. All three fusions reported
in human synovial sarcomas (SSX1,2,4) produced BAF47 evic-
tion, whereas SS18-SSX3 and SS18-SSX5 (which bears an
amino acid change in the last 8 aa of SSX) fusions did not
(Figures S5A and S5B).
Reversibility of BAF Complex Subunit Composition and
Targeting in Human Synovial Sarcoma
Our observation that SS18 was displaced or failed to assemble
into BAF complexes in the presence of somewhat higher
concentrations of the SS18-SSX fusion protein (Figures 2C and
3F) led us to investigate the possibility that the transforming
fusion protein and the wild-type protein might exist in a concen-
tration-dependent equilibrium or could be competing for
assembly into newly formed complexes. Urea-based denatur-
ation experiments demonstrated that SS18 and SS18-SSX are
both stably bound to BAF complexes and dissociate to compa-
rable degrees from 0 to 8 M urea as shown by immunoblot and
quantitative densitometry analyses (Figures 6A, 6B, and S6).
BAF complex components dissociated at comparable levels
across the urea denaturation series from V5-tagged SS18 and
SS18-SSX, indicative of equal affinity binding of wild-type
SS18 and SS18-SSX (Figure 6C). Moreover, Brg and b-actin re-
mained bound to V5-SS18/SS18-SSX-purified complexes to
>5 M urea, suggesting that SS18/SS18-SSX is part of a highly
stable core complex of Brg, BAF53a, and b-actin.
Given these findings and having observed that shRNA-medi-
ated KD of the SS18-SSX1 fusion could restore BAF47 total
protein levels (Figure 3G), we sought to determine whether over-
expression of wild-type SS18 could also be sufficient to allow
normal complexes to reform in synovial sarcoma cell lines and
whether this could reverse the misassembly of synovial sarcoma
BAF complexes and correct the gene expression phenotypes.
Intriguingly, introduction of SS18 FL or SS18 1–379 resulted in
a profound increase in BAF47 total protein levels by day 10 post-
infection (Figure 6D, left). Moreover, BAF complexes in Aska-SS
cells infected with SS18 regained normal incorporation of wild-
type SS18 and BAF47 subunits, suggesting concentration-
driven reintegration of SS18 (Figure 6D, right). Introduction of80 Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc.SS18-SSX1 into 293T fibroblasts resulted in reduction of
BAF47 total protein to a comparable degree as shRNA-mediated
KD of BAF47 (Figure 6E). These studies indicate that the SS18-
SSX fusion protein and the wild-type SS18 protein compete for
assembly into BAF complexes and that the transforming fusion
protein can be displaced from BAF complexes to yield wild-
type complexes by increasing the concentration of the wild-
type SS18 protein.
Proliferation of SS cells was inhibited by introduction of wild-
type SS18 and SS18 1–379, to a similar degree as in cells treated
with shRNA-mediated KD of the SS18-SSX1 fusion (Figure 6F).
In contrast, introduction of SS18-SSX into SS18-SSX-bearing
synovial sarcoma Aska-SS cells had no appreciable effect on
proliferation as compared to control. Sox2 mRNA expression
levels in Aska-SS cells were reduced by 3- and 4-fold, upon
overexpression of SS18 FL and SS18 1–379, respectively
(Figure 6G). In contrast, overexpression of SS18-SSX1 in these
lines already bearing one translocated allele caused Sox2
mRNA levels to increase 1.7-fold above control levels relative
to empty vector control, indicating that the levels of Sox2
produced by the SS18-SSX fusion protein were not at maximum.
Finally, Aska-SS cells infected with SS18 FL to reverse the BAF
complex phenotype exhibited a dramatically decreased occu-
pancy of BAF complexes at the human Sox2 locus with
a concomitant increase in H3K27me3 occupancy (Figure 6H).
These studies indicate that normal BAF complexes can be reas-
sembled in malignant cells by overexpression of the wild-type
SS18 protein, leading to BAF complex removal from the Sox2
gene and resumption of normal repression of Sox2 by H3K27
trimethylation.
Finally, we aimed to test the potential for BAF47 overexpres-
sion to promote reassembly of wild-type BAF complexes con-
taining BAF47 and SS18 in SS cells and its effect on proliferation.
Notably, overexpressed V5-tagged BAF47 was unable to bind
SS18-SSX-containing complexes in both SS cell lines tested,
as evidenced by low protein levels on complexes detected by
anti-Brg and anti-V5 immunoprecipitations as well as by total
protein immunoblots, suggestive of rapid degradation (Fig-
ure 7A). To test whether shifting aberrant complex assembly
back to that of wild-type would allow for integration of the exog-
enous BAF47-V5 into complexes, we infected SS cells contain-
ing BAF47-V5 with either SS18 FL or shSS18-SSX. Indeed, in
both lines, overexpression of SS18 FL or KD of the SS18-SSX
fusion resulted in increased incorporation and stabilization of
BAF47-V5 as indicated by anti-Brg immunoprecipitation (Fig-
ure 7B). Intriguingly, BAF47 overexpression had no effect on
SS cell proliferation in culture; however, proliferation was
dramatically attenuated upon cointroduction of overexpressed
SS18 FL or KD of SS18-SSX, suggesting that BAF47 can only
assemble into wild-type SS18-containing complexes and not
complexes bearing the SS18-SSX fusion (Figure 7C).
DISCUSSION
Our studies demonstrate that in the two synovial sarcoma cell
lines we have used, the fusion of SS18 with SSX, which is diag-
nostic of this tumor type, leads to assembly of aberrant BAF
complexes that become targeted to the Sox2 locus, with loss
A B
C D
E F G
H
Figure 6. Reversible Integration, Gene Expression, and Occupancy by SS18 and SS18-SSX Containing mSWI/SNF (BAF) Complexes
(A) Denaturation studies using 0–8 M urea with subsequent immunoblot analysis for SS18 in 293T cells and SS18-SSX in Aska-SS cells. See also Figure S6.
(B) Quantitative densitometry of SS18 or SS18-SSX1 protein immunoblots from n = 3 experimental replicates of urea denaturation 0 < [urea] < 8 M. y axis: band
quantitation/untreated control. Error bars = SD.
(C) IP using anti-V5 antibody in urea-treated nuclear extracts isolated from 293T fibroblasts infectedwith either V5-SS18 or V5-SS18-SSXwith immunoblotting for
BAF complex components.
(D) Left: Immunoblot analysis on total protein isolated from Aska-SS cells with either SS18 or SS18 1-379 or SS18-SSX1 introduced via LV. Right: Anti-Brg IP of
complexes in either empty vector or V5-SS18-FL-treated conditions.
(E) Introduction of SS18-SSX1 and shBAF47 into 293T cells with subsequent immunoblot analysis on total protein.
(F) Cell proliferation analyses of Aska-SS cells infected with control vector, SS18, SS18 1-379, and SS18-SSX. Error bars = SD.
(G) Sox2 mRNA relative expression (normalized to GAPDH) 10 days postinfection with LV containing either control shScramble or overexpression of SS18, SS18
1-379, or SS18-SSX. Error bars = SD.
(H)Left:Anti-BAF155ChIPonAska-SScells treatedwitheitherempty vectororSS18FL,withsubsequentqPCRfor regionsat thehumanSox2promoterand twoSox2
transcription factor (TF)bindingsiteswithin theexon.Right:Anti-H3K27me3ChIPatSox2 locus inAska-SScontrol-treatedandSS18FL-treatedcells.Errorbars=SD.
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Figure 7. A Model for Reversible Transfor-
mation by the SS18-SSX1Oncogenic Fusion
(A) Left: Anti-Brg IPs on 293T, B35, Aska-SS, and
Yamato-SS cells bearing introduced BAF47-V5.
Middle: Anti-V5 IPs. Right: Total protein inputs.
(B) Anti-Brg IPs on nuclear extracts of Aska-SS
and Yamato-SS cells with stably introduced
BAF47-V5 and coinfection with either control
vector, SS18 FL, or shSS18-SSX.
(C) Proliferation analyses of Aska-SS cells infected
with control vector, BAF47-V5, or BAF47-
V5+coinfected SS18 FL, BAF47-V5+coinfected
shSS18-SSX. Error bars = SD.
(D) Model for reversible disruption of BAF complex
composition and action upon SS18-SSX incorpo-
ration.of repressive H3K27me3 marks, which drives Sox2 expression
and proliferation of these cells (Figure 7D). The observation
that Sox2 is activated in all SS studied (Naka et al., 2010)
suggests this is a general mechanism of oncogenesis in these
tumors. We find that the SS18-SSX fusion incorporates into
BAF complexes and activates Sox2 expression, explaining the
uniform activation of this gene in SS. But, how do complexes
containing the SS18-SSX fusion activate Sox2? BAF complexes
containing the SS18-SSX fusion could be targeted by the
interaction of SSX with a factor that binds the Sox2 locus.
Alternatively, an incorrectly assembled complex could target
the Sox 2 locus by changes to bromo-, chromo-, and PHD
domain presentation. We find that the 78 aa of SSX alone are
not targeted to the Sox2 locus when expressed in human
fibroblasts (Figure S4B), indicating that it is the aberrantly
assembled complex that targets the inactive Sox2 locus,
reversing H3K27Me3-mediated repression, and leading to
Sox2 activation.
Remarkably, the wild-type SS18 protein is capable of replac-
ing the SS18-SSX fusion in BAF complexes when expressed at
somewhat higher levels than the fusion protein. The incorpora-
tion of wild-type and mutant proteins is unlikely to be due to82 Cell 153, 71–85, March 28, 2013 ª2013 Elsevier Inc.direct binding competition. This conclu-
sion arises from the fact that 8 M urea
is required to remove either the wild-
type SS18 protein from the wild-type
complexes or the SS18-SSX fusion from
the malignant complexes. Hence, the
two proteins most likely compete for
assembly into complexes, with the prod-
uct of the fusion allele winning in SS cells
because of increased concentration.
The ability of SS18-SSX to disrupt BAF
complexes maps to two regions of
the SSX protein: the C-terminal 8 aa
(SDPEEDDE) and a polar region of 2 aa
present in the oncogenic members of
the SSX family of proteins. Substitution
of KR with MI, found in the nontransform-
ing SSX3, restores normal complex
assembly and gene regulation; substitu-tion of MI with KR in SS18-SSX3 results in BAF47 ejection and
increased Sox2 mRNA. In this regard, SSX5 is interesting in
that it has amino acids lysine (K) and threonine (T) at position
43, 44, combined with an amino acid substitution of P for E in
the 8 terminal aa; SS18-SSX5 has not been found in transloca-
tions and does not eject BAF47, confirming the importance of
both regions for oncogenicity. These two regions could interact
to facilitate complex dissolution or form dimers in the malignant
complexes. Structural studies will be necessary to define the
precise mechanism. However, the ability of such a small region
to lead to complex dissolution and the observation that the
wild-type and malignant proteins are in a dynamic equilibrium
indicates that the fusion containing the 2 aa essential region in
the SSX tail (K43, R44) is an excellent target for developing ther-
apeutics for this disease. A decoy molecule that causes SSX1 to
resemble SSX3 would be expected to prevent eviction of BAF47
and thereby reverse the effects of the aberrant SS-BAF complex.
This notion is consistent with the precision of the oncogenic
translocation in that all translocations discovered to date add
exactly 78 aa of SSX1,2 or 4 to the SS18 protein at position 379.
In SS cells, the partially assembled complex gains the
ability to bind the Sox2 gene, reversing H3K27Me3-mediated
repression. Forcing correct assembly by expressing the wild-
type SS18 causes the reassembly of wild-type complexes
without the fusion, thus re-establishing normal repression of
Sox2 by polycomb. The fly Brahma protein was discovered
from its ability to oppose polycomb and hence is known as a tri-
thorax gene; however, the underlying biochemical mechanisms
have been controversial. In some studies, polycomb was found
to prevent Brahma (BAP) complex binding, whereas in others it
seemed that BAP or SWI/SNF directly recruited PolII, thereby
opposing polycomb. Our studies suggest that somehow BAF
complexes evict polycomb; however, our temporal resolution
is limited to the infection times (24–72 hr), and hence we are
unable to determine if the mechanism is direct physical eviction
or dilution of H3K27Me3 by nucleosome exchange with cell
division because the measured rates of nucleosome turnover
(Deal et al., 2010) are sufficient to remove most H3K27Me3 if
methylation were prevented by the SS BAF complex. Evidence
for BAF-polycomb opposition in malignancy has also been
found with inactivation of BAF47 (hSNF5 or Ini1) in human
malignant rhabdoid sarcoma (MRTs). In these tumors and in
mouse models, polycomb was found to be removed from the
INK4a locus upon introduction of BAF47 (hSNF5) (Kia et al.,
2008). Understanding the underlying mechanism of polycomb
opposition will require techniques that allow rapid recruitment
of BAF complexes with a high degree of temporal and spatial
control (Hathaway et al., 2012).
Synovial sarcoma is largely resistant to conventional, chemo-
therapy-based forms of treatment, underlining the need for an
understanding of its pathogenesis. Disease-specific biologic
agents that target SS18-SSX or its interactions have not been
developed to date. Here, we have shown that the SS18-SSX1
oncogenic fusion usurps SWI/SNF-like BAF complexes, result-
ing in activation of Sox2, which drives proliferation. Remarkably,
the oncogenic fusion andwild-type SS18 bind to BAF complexes
with comparable affinities, allowing directed assembly of onco-
genic or wild-type complexes. Moreover, the composition of
SS18-SSX-containing BAF complexes (lacking BAF47 and
wild-type SS18) can be reversed by reducing the levels of
SS18-SSX or by increasing levels of wild-type SS18. The obser-
vation that eviction of BAF47 from the complexes is dependent
upon only 2 aa in SSX demonstrates an unusual mechanism of
oncogenesis and opens a potential therapeutic avenue.EXPERIMENTAL PROCEDURES
Nuclear Extract Preparation and Proteomic Studies
Nuclear extract (NE) preparation and immunoprecipitation (IP) studies were
performed as described in Ho et al. (2009) and Extended Experimental Proce-
dures. Antibody specifications are presented in Table S1.
Transfection Studies
Briefly, cells were plated in 6-well plates to 80% confluence prior to transfec-
tion using polyethylenimine (PEI) in a 3:1 PEI:DNA ratio and were harvested at
the appropriate time points thereafter.
Cell Proliferation Analyses
Cells were assessed for >95% viability prior to being plated at 105 cells/well in
triplicate/condition in 12-well plates. Cell counts were determined using trypan
blue exclusion-based methods.Urea Denaturation Studies
NEs (150 mg) were subjected to partial urea denaturation, ranging from 0.25 to
8 M urea (in IP buffer), for 15 min at room temperature (RT) prior to anti-Brg IP.
The coprecipitated proteins were analyzed by immunoblot. Quantitative densi-
tometry analyses were performed with the Li-Cor Oddessy Imaging System
(Li-COR Biosciences, Lincoln, NE, USA).
Density Sedimentation Analyses
NE (800 mg) was resuspended in 300 ml of 0% glycerol HEMG buffer and care-
fully overlaid onto a 10 ml 10%–30% glycerol (in HEMG buffer) gradient
prepared in a 14 3 89 mm polyallomer centrifuge tube (331327, Beckman
Coulter, Brea, CA, USA). Tubes were centrifuged in an SW40 rotor at 4C for
16 hr at 40 K rpm. Fractions (0.5 ml) were collected and used in analyses.
See Extended Experimental Procedures.
Cyclohexamide/MG-132 Studies
MG-132 (474790, Calbiochem, San Diego) (10 mg/ml in DMSO) was used at
1:1,000, and cyclohexamide (C4859, Sigma-Aldrich, St. Louis) (100 mg/ml)
was used at 1:100 in cell culture media. Briefly, cells were plated in 6-well
plates and treated with the above agents for 0 to 24 hr and harvested with
RIPA lysis buffer.
Gene Expression Profiling and Analysis
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA)
and reverse transcribed into cDNA (SuperScript III RT kit, Invitrogen). Real-
time PCR was performed using TaqMan Universal Master Mix with Taqman
probes and/or SYBR green method with custom-designed primers, normal-
ized to GAPDH and/or 18S rRNA expression. All primers are listed in Table S2.
shRNA-Mediated Knockdown and Lentiviral Generation
shRNAs specific for human Brg1, BAF47, SS18, and Sox2 were purchased
from Open Biosystems (Thermo Scientific, Waltham, MA, USA) (Table S3).
shRNA KD constructs for SS18-SSX and shScramble control were generated
by annealed oligos (Table S3) and subsequent cloning into the pLK0.1 vector.
Lentiviral (LV) was produced as described by Tiscornia et al., 2006. See
Extended Experimental Procedures.
ChIP Analyses
Briefly, cells were crosslinked in formaldehyde, washed, and sonicated as
described in Extended Experimental Procedures. Antibodies used for ChIP
studies include anti-BAF155 (in-house generated), anti-H3K27me3 (07-449,
Millipore, Billerica, MA, USA), and V5 (46-0705, Invitrogen). Primers used for
real-time PCR are listed in Table S2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, and three tables and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2013.02.036.
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